C

Clinica Universidad de Navarra | Sede Madrid - Hematology Department

Research site
(Unclaimed)
Location
Calle Marquesado de Santa Marta, 1, Madrid, Madrid, Spain
Site insights

Top conditions

Plasma Cell Cancer (7 trials)

Cancer (7 trials)

Multiple Myeloma (7 trials)

Lung Cancer (6 trials)

Lymphoma (6 trials)

Top treatments

Lenalidomide
Daratumumab
Platinum
Nivolumab
Dexamethasone
Pembrolizumab
Carboplatin
Cemiplimab
Cisplatin
Paclitaxel

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

47 of 64
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during...

Enrolling
Marginal Zone Lymphoma
Follicular Lymphoma
Biological: rituximab
Biological: EO2463

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: sotorasib
Drug: Anti PD-1/L1

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on v...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Apixaban

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembol...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Dalteparin

This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary...

Enrolling
Advanced Cancer
Solid Tumor, Adult
Drug: MCLA-145

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advan...

Active, not recruiting
Solid Tumor
Colorectal Adenocarcinoma
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Aut...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab an...

Enrolling
Carcinoma, Hepatocellular
Drug: Relatlimab
Drug: Bevacizumab

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearr...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Pemetrexed

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with...

Active, not recruiting
Medullary Thyroid Cancer
Drug: Selpercatinib
Drug: Vandetanib

The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in...

Active, not recruiting
Squamous Cell Carcinoma of the Head and Neck
Drug: Placebo
Drug: Xevinapant (Debio 1143)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with r...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Zanubrutinib

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Enrolling
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MT...

Enrolling
Advanced Solid Tumors
Drug: Debio 0123

The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multipl...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Nirogacestat

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-c...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Dexamethasone

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Enrolling
Follicular Lymphoma (FL)
Drug: Odronextamab
Drug: Rituximab

This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combi...

Enrolling
Ovarian Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells
Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. Th...

Active, not recruiting
Early Alzheimer's Disease
Drug: Experimental: ALZ-801
Drug: Placebo Comparator: Placebo

Trial sponsors

U

University of Navarra (7 trials)

Pfizer logo

Pfizer (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems